Zacks: Analysts Expect Alcentra Capital Corp (NASDAQ:ABDC) Will Post Quarterly Sales of $6.19 Million
Wall Street brokerages forecast that Alcentra Capital Corp (NASDAQ:ABDC) will announce sales of $6.19 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Alcentra Capital’s earnings, with estimates ranging from $6.01 million to $6.38 million. Alcentra Capital posted sales of $6.55 million in the same quarter last year, which suggests a negative year over year growth rate of 5.5%. The business is expected to report its next earnings results on Monday, November 4th.
On average, analysts expect that Alcentra Capital will report full-year sales of $25.04 million for the current financial year, with estimates ranging from $24.54 million to $25.46 million. For the next financial year, analysts expect that the firm will post sales of $25.92 million, with estimates ranging from $24.50 million to $26.93 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Alcentra Capital.
Alcentra Capital (NASDAQ:ABDC) last posted its earnings results on Wednesday, August 7th. The asset manager reported $0.20 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.20. Alcentra Capital had a return on equity of 8.30% and a net margin of 31.91%. The company had revenue of $6.14 million for the quarter, compared to analysts’ expectations of $6.11 million.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its holdings in shares of Alcentra Capital by 40.8% during the 2nd quarter. Acadian Asset Management LLC now owns 17,196 shares of the asset manager’s stock valued at $145,000 after buying an additional 4,985 shares during the last quarter. Pacific Ridge Capital Partners LLC lifted its holdings in Alcentra Capital by 2.4% in the 2nd quarter. Pacific Ridge Capital Partners LLC now owns 456,870 shares of the asset manager’s stock worth $3,829,000 after purchasing an additional 10,918 shares during the last quarter. Appleton Partners Inc. MA acquired a new stake in Alcentra Capital in the 2nd quarter worth approximately $89,000. Finally, Morgan Stanley lifted its holdings in Alcentra Capital by 120.8% in the 2nd quarter. Morgan Stanley now owns 438,715 shares of the asset manager’s stock worth $3,676,000 after purchasing an additional 240,027 shares during the last quarter. 38.17% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ ABDC traded down $0.07 during midday trading on Friday, reaching $8.77. 101 shares of the company traded hands, compared to its average volume of 39,832. Alcentra Capital has a 52 week low of $5.58 and a 52 week high of $9.40. The stock has a 50-day moving average price of $8.90 and a 200 day moving average price of $8.43. The company has a market cap of $113.86 million, a price-to-earnings ratio of 8.70 and a beta of 0.55.
The business also recently declared a quarterly dividend, which was paid on Thursday, October 3rd. Investors of record on Thursday, September 26th were paid a $0.18 dividend. The ex-dividend date was Wednesday, September 25th. This represents a $0.72 dividend on an annualized basis and a yield of 8.21%. Alcentra Capital’s dividend payout ratio is currently 71.29%.
About Alcentra Capital
Alcentra Capital Corporation is a business development company specializing in investments in lower middle-market companies. The fund seeks to invest in healthcare, business services, defense, government services, telecom and technology, media, infrastructure maintenance and logistics, and oil and gas services sector.
Recommended Story: The role of implied volatility with call option volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.